Please login to the form below

OPEN Health announces the integration of Pharmerit International into the group

OPEN Health has today announced the integration of Pharmerit International, a global leader in health economics and outcomes research (HEOR), into its group of companies.

OPEN Health has today announced the integration of Pharmerit Internationala global leader in health economics and outcomes research (HEOR), into its group of companies. Joining the Pharmerit business with the OPEN Health Group establishes a new unique entity equipped to be a global leader in HEOR, market access, medical affairs and healthcare communications.

The merger enhances and supports OPEN Health’s positioning – deep, broad and connected:

  • Deep in that integration will expand the company’s global footprint and capabilities in the HEOR and market access space – across four integrated centres of excellence:
    • Strategic market access
    • Modelling and meta-analysis
    • Real world evidence
    • Patient centred outcomes

    Bringing together strategic and technical expertise to build the evidence needed to demonstrate the unmet needs and the value of therapies.

  • Broad in terms of the ability to offer HEOR and Medical Affairs clients a truly comprehensive suite of materials to identify and address evidence gaps and deliver world class communications across a wide range of media.
  • Connected as there will be a highly skilled and diverse team working together across the globe to deliver truly innovative and best-in-class solutions to our clients. Strong interpersonal and cultural fit are the underpinnings of the business integration, with shared values around collaboration and intellectual curiosity.

In terms of scale, the integration means OPEN Health will now consist of 700 people in 15 offices across 6 different countries including US, UK, The Netherlands, Germany, India and China.

OPEN Health is a portfolio company of Amulet Capital Partners, LP, a US-based private equity firm focused exclusively on the healthcare sector.

Sandy Royden, Chief Operating Officer at OPEN Health comments, “We are delighted to welcome Pharmerit into the OPEN Health family – this is a key strategic integration – that will both enhance our global HEOR offering and also our global Medical Affairs Platform. OPEN Health now has a unique mix of offerings and opportunities for innovation, to support industry changes and growth.”

Jenny Stephens, Partner at Pharmerit International comments, “We are very excited about Pharmerit joining the OPEN Health family. The two organizations have many synergies and fill important gaps for each other. By combining our capabilities and expertise, we will increase our global presence and expand the services we offer clients today.”

Marc Botteman, Partner at Pharmerit International said, "Over the past two decades, we have proudly grown Pharmerit into a global strategic leader dedicated to our mission of demonstrating and communicating the value of innovative healthcare interventions with the development of rigorous evidence. In joining OPEN Health, we are significantly expanding our client base and will be able to provide a wider range of integrated services to our clients, notably the medical affairs groups. We very much look forward to working with the OPEN Health management and Amulet teams to contribute to the long-term growth of OPEN Health.”

Ben van Hout, Partner at Pharmerit International comments, “This is an exciting time for Pharmerit. The integration builds on our unique value proposition as a multi-disciplinary, end-to-end, HEOR and market access leader, and strengthens our ability to innovate and deploy new analytic techniques for clients.”

Pink divider

Contact:

Sandy Royden, COO, OPEN Health
Email: sandyroyden@openhealthgroup.com
Tel: +44 1628 481112

Candice Subero, Marketing Director, Pharmerit International
Email: csubero@pharmerit.com
Tel: +1 240-483-4323

About OPEN Health Communications LLP:

OPEN Health is a multi-disciplinary health communications and market access group, operating within three core business areas: Medical Communications; Patient and Brand Communications; and Value, Informatics and Evidence. OPEN Health was formed in 2011, and whilst working across a broad therapeutic range has a strong focus on oncology, rare diseases and specialist medicines.

For more information on OPEN Health, please visit www.openhealthgroup.com.

About Pharmerit International:

Pharmerit International is a global, premier health economics and outcomes research (HEOR) consultancy with 20 years of experience supporting pharmaceutical, biotechnology, and medical device organizations in health economics and outcomes research (HEOR) and market access worldwide. Pharmerit delivers quality research across four multi-disciplinary Centres of Excellence; Modelling & Meta-Analysis, Patient-Centred Outcomes, Real-World Evidence, and Strategic Market Access. Pharmerit has offices in Berlin, Bethesda, Boston, Mumbai, New York, Rotterdam, York, and Shanghai.

For further information on Pharmerit International, please visit www.pharmerit.com

4th November 2019

Share

Tags

Company Details

OPEN Health

+44 1628 481112

Contact Website

Address:
The Weighbridge
Brewery Courtyard
High Street
Marlow
Buckinghamshire
SL7 2FF
United Kingdom

Latest content on this profile

Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications
OPEN Health
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.
OPEN Health
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest. This blog has been written to provide commentary on a topical issue relating to the use of Patient-Reported Outcomes (PROs) in oncology trials.
OPEN Health
Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma
OPEN Health
OPEN Health reflections on the World Orphan Drug Congress in Barcelona
Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications practices took away from the discussions and presentations.
OPEN Health
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the care pathway for a patient, there appear to be inconsistencies within the same pharmaceutical organisations as to how patient journey mapping is defined.
OPEN Health